Magellan empowers clinicians to reduce patients pain and enhance mobility
Take the journey with us and invest in enriching lives.
Our product MAG200 will improve the lives of people across the globe who are currently living with joint pain and issues with mobility.
Osteoarthritis is the leading cause of pain, disability, and early retirement in more than 100+million people in the developed world. The osteoarthritis pharmaceutical therapeutics market size was $9+ billion per annum in 2020 and projected to grow to $14+ billion per annum by 2025.
Magellan Stem Cells is at the forefront of stem cell research for osteoarthritis globally. We are leading the way in scientific, clinical and commercial expertise for stem cell supply and development, for both autologous treatments which use the patient’s own cells, and allogeneic treatments which use selected donor cells.
Osteoarthritis is globally recognised as an unmet clinical need. In Australia alone, more than 2.2 million people are suffering with osteoarthritis and $3.4 billion is spent annually on osteoarthritis treatments, with half of this on joint replacements. The economic burden to Australia in direct and indirect costs is $23.9 billion per annum and it is now a National Health Priority.
The cost of osteoarthritis is more than 1% p.a. of GDP in developed nations and is now a National Health Priority in Australia. The average non-surgical medical cost per patient is $5.9K p.a USD.
The osteoarthritis pharmaceutical therapeutics market is growing rapidly, with $7.3B spent in 2020 and projected to increase to $11B p.a. by 2025.
Additionally, the data and experience from the treatment of more than 800 autologous patients, has enabled the identification of optimum donor cells, to use in our allogeneic phase 1-3 research and treatment of osteoarthritis.
Additionally, the data and experience from the treatment of more than 1000 autologous patients, has enabled the identification of optimum donor cells, to use in our allogeneic P1/2/3 research trials for the treatment of osteoarthritis.
Osteoarthritis is increasing
100M+ people in developed world and >650M globally have OA. 20% of people are over 45 years and 80% of people are over 65 years.
Current treatments have poor efficacy
Treatments used today have limited short term pain improvement with no disease modification and a potential risk of significant side effects.
Largest healthcare cost to society
The cost of osteoarthritis is more than 1% p.a. of GDP in developed nations and is now a National Health Priority in Australia. The average non-surgical medical cost per patient is $5.9K p.a USD.
High growth global market
The osteoarthritis pharmaceutical therapeutics market is growing rapidly, with $9B spent in 2020 and projected to increase to $14B p.a. by 2025.
About
Magellan Stem Cells is a private Australian company with expertise in research, development and manufacturing of stem cell therapies for the treatment of osteoarthritis.
We lead the way globally in scientific, clinical, and commercial expertise for stem cell supply and product development. Magellan Stem Cells value is its knowledge and experience in the efficient and low- cost culturing of stem cells. Additionally, the data and experience from the treatment of more than 1000 autologous patients, has enabled the identification of optimum donor cells, to use in our allogeneic phase 1-3 research and treatment of osteoarthritis.
Magellan Stem Cells current autologous treatments for osteoarthritis have shown in our patient clinical trials:
- Substantial pain relief
- Improvement in function and mobility
- Halting of disease progression with the potential of delay and/or possible elimination of the need for expensive joint replacement surgery.
